Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VS035
- Development stage
- Preclinical
- Lead developer
- RDP Pharma
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
VS035 is a first-in-class, orally available small molecule protein degrader being developed by RDP Pharma for the treatment of HPV-induced malignancies. The drug is designed to target and degrade the HPV E7 oncoprotein, a critical driver of oncogenesis that is consistently expressed in HPV-driven cancers such as cervical cancer, vulvar cancer, and anal intraepithelial neoplasia. VS035 was developed using RDP Pharma's proprietary PROMPT (Protein Modulation via Proximity Targeting) platform, which is specifically engineered to target intrinsically disordered region (IDR) proteins that were previously considered undruggable. By inducing the proteasomal degradation of the E7 oncoprotein, VS035 aims to eliminate the primary driver of HPV-associated tumor growth and maintenance. The drug is currently in preclinical development.
- Other names
- HPV E7 Degrader
02
Targets
E7 (Papillomavirus E6/E7 oncoproteins)
Beyond the preview
Go deeper on VS035.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VS035.